Korea Ups Tax Credits, R&D Support, Seeks UK Collaboration
This article was originally published in PharmAsia News
Amid concerns South Korea may be lagging behind in innovation due to sluggish R&D investment, the government is making domestic and international efforts to beef up R&D support for the biopharma sector. It plans to expand R&D-related tax incentives and will conduct joint R&D projects with the UK's Medical Research Council, which sees the country as an important strategic partner.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.